All posts by GTCbio


Advances in Parkinson’s Disease Research and Therapeutics

GTCbio | July 20th, 2017

Parkinson’s disease, the second-most common neurodegenerative disorder affecting 2–3% of the population ≥65 years of age has seen significant developments in past few years in terms of diagnosis and therapeutics. The collaboration between the European Human Brain Project and the U.S. Brain Initiative may result in a milestone for brain related diseases just as the…read more